Related references
Note: Only part of the references are listed.Long-term Antipsychotic Treatment and Brain Volumes A Longitudinal Study of First-Episode Schizophrenia
Beng-Choon Ho et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia
Yechiel Levkovitz et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
The NADPH Oxidase NOX2 Controls Glutamate Release: A Novel Mechanism Involved in Psychosis-Like Ketamine Responses
Silvia Sorce et al.
JOURNAL OF NEUROSCIENCE (2010)
Minocycline 1-Year Therapy in Multiple-System-Atrophy: Effect on Clinical Symptoms and [11C] (R)-PK11195 PET (MEMSA-Trial)
Richard Dodel et al.
MOVEMENT DISORDERS (2010)
Neurocognitive Effectiveness of Haloperidol, Risperidone, and Olanzapine in First-Episode Psychosis: A Randomized, Controlled 1-Year Follow-Up Comparison
Benedicto Crespo-Facorro et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
IQ as a predictor of functional outcome in schizophrenia: A longitudinal, four-year study of first-episode psychosis
Verity C. Leeson et al.
SCHIZOPHRENIA RESEARCH (2009)
Microglia Activation in Recent-Onset Schizophrenia: A Quantitative (R)-[11C]PK11195 Positron Emission Tomography Study
Bart N. van Berckel et al.
BIOLOGICAL PSYCHIATRY (2008)
N-acetyl cysteine as a glutathione precursor for schizophrenia - A double-blind, randomized, placebo-controlled trial
Michael Berk et al.
BIOLOGICAL PSYCHIATRY (2008)
Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review
Stephane Potvin et al.
BIOLOGICAL PSYCHIATRY (2008)
Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study
Tsuyoshi Miyaoka et al.
CLINICAL NEUROPHARMACOLOGY (2008)
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
Paul H. Gordon et al.
LANCET NEUROLOGY (2007)
Arnoxapine as an antipsychotic - Comparative study versus holoperidol
Imran B. Chaudhry et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2007)
Minocycline treatment in acute stroke - An open-label, evaluator-blinded study
Y. Lampl et al.
NEUROLOGY (2007)
Focal gray matter changes in schizophrenia across the course of the illness: A 5-year follow-up study
Neeltje E. M. van Haren et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine
Lin Zhang et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia
Yechiel Levkovitz et al.
BRAIN RESEARCH (2007)
Calprotectin in microglia from frontal cortex is up-regulated in schizophrenia: evidence for an inflammatory process?
Russell Foster et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
Brain volume changes in the first year of illness and 5-year outcome of schizophrenia
W. Cahn et al.
BRITISH JOURNAL OF PSYCHIATRY (2006)
Baseline neurocognitive deficits in the CATIE schizophrenia trial
Richard S. E. Keefe et al.
NEUROPSYCHOPHARMACOLOGY (2006)
Association of schizophrenia and autoimmune diseases: Linkage of Danish National Registers
WW Eaton et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients
LS Pilowsky et al.
MOLECULAR PSYCHIATRY (2006)
Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo
SH Choi et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Antipsychotic drug effects on brain morphology in first-episode psychosis
JA Lieberman et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
Cognitive-behavioural therapy in first-episode and early schizophrenia - 18-month follow-up of a randomised controlled trial
N Tarrier et al.
BRITISH JOURNAL OF PSYCHIATRY (2004)
Neuroprotection by tetracyclines
M Domercq et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development
JH Krystal et al.
PSYCHOPHARMACOLOGY (2003)
Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation
GE Duncan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison
C Pantelis et al.
LANCET (2003)
A separate disease within the syndrome of schizophrenia
B Kirkpatrick et al.
ARCHIVES OF GENERAL PSYCHIATRY (2001)
Share Paper
